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Introduction
Vaccine effectiveness (VE) against H3N2 viruses is typically lower than VE against influenza H1N1 and/or influenza B viruses. It's not uncommon to see VE of about 30 percent against H3N2 viruses. Furthermore, during the flu season 2017 in Australia, VE of the seasonal flu vaccine was around 10% resulting in record-high numbers of laboratory-confirmed influenza A infections, hospitalizations and deaths 1 . This situation raised concerns that similar could happen in the United States during the flu season 2017/2018, in which H3N2 viruses were predominant. The concerns were based on assumptions that H3N2 viruses in Australia and US were similar, as the classical phylogeny indicated, and because the vaccine composition was identical one could expect comparable levels of VE. Therefore, predicted VE of the flu vaccine in the USA at the beginning of the flu season was around 10%
2 . This prediction was justified and rationalized using the assumption that H3N2 viruses circulating in Australia in the flu season 2016-17 are similar to viruses in the Northern Hemisphere.
Comparison of Australian H3N2 viruses and viruses isolated in the USA at the beginning of the flu season 2017-18, performed using a novel functional phylogenetic tool, demonstrated significant difference between these two groups of viruses 3 . This new information led us to predict that the flu vaccine in US should work in the season 2017-18 just as well as in 2016-17 3 . Our prediction was recently confirmed in the interim CDC estimation of 2017-18 seasonal influenza VE, published and released in February 2018 1 . Moreover, the risk for a (H3N2) associated medically-attended influenza illness was reduced through vaccination by 59% among children aged 6 months through 8 years In order to assess VE against H3N2 viruses for the next flu season 2018-19 in the United States, we analyzed compatibility between new vaccine virus A/Singapore/INFIMH-16-0019/2016 and H3N2 viruses isolated in 2018 in US. This analysis was performed using the informational spectrum method (ISM) based phylogenetic algorithm, the Informational Spectrum-based Phylogenetic Analysis (ISTREE), which we previously used to assess VE for the flu season 2017-18 3 . This algorithm, which is based on the informational hallmark of proteins that determines their biological function, was previously described in more detail 4 .
Results and discussion
In Figure 1 the ISM-based phylogenetic tree is presented for hemagglutinin HA1 from 68 H3N2 viruses collected in the United States from January to February 2018 and stored in the publicly open database GISAID. As can be seen in this figure, the H3N2 viruses are grouped into two separate clusters and the novel vaccine virus A/Singapore/INFIMH-16-0019/2016 belongs to the small cluster encompassing only 8.8% of analyzed viruses. Previously we showed that 71% of H3N2 viruses isolated in the beginning of the US season 2017-18 were informationally compatible with vaccine virus 3 . This compatibility resulted in good protection against H3N2 viruses in this season We propose the "ISM-based phylogenetic algorithm ISTREE analysis" for rapid and accurate analysis of different influenza A viruses that can be used for VE prediction. This is a first report VE prediction prior to flu season using computational analysis. Our prediction has been recently confirmed through laboratory reports released by CDC. Based on current data, we predict low VE for the season 2018/2019 for US due to vaccine virus selection. 
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In fact, such algorithms would be of great interest and value in terms of vaccine selection. The prospective statements re appropriate vaccine strains for a future influenza season made by the authors here are quite clear but they are solely based on ISTREE assessments. No flanking/supporting data based on standard HI assays is provided. Assessing the validity of the ISTREE data therefore is not possible. The data may well turn out to be useful but, as it currently stands, they may be totally misleading as well.
Solid antigenic data will be required to validate the potentially useful ISTREE algorithm. 
